| 75 | 6 | 8 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:探讨不同剂量伐地那非治疗新生儿持续肺动脉高压的临床疗效。方法:选择2013年8月~2017年4月在本院确诊并接受治疗的持续肺动脉高压新生儿60例,均接受伐地那非治疗并根据药物剂量不同分为低剂量组(2.5mg)、中等剂量组(5mg)、大剂量组(10mg),各20例。对比3组患儿治疗1个月后肺动脉收缩压(PASP)水平,外周血中心肌损伤标志物、内皮损伤指标含量的差异。结果:治疗1个月后,大剂量组患儿的PASP水平低于中等剂量组、低剂量组;外周血中心肌损伤标志物高敏肌钙蛋白T(hs-cTnT)、B型尿钠肽(BNP)、乳酸脱氢酶(LDH)含量低于中等剂量组、低剂量组;外周血中内皮损伤指标内皮素-1(ET-1)、缺氧诱导因子-1α(HIF-1α)含量低于中等剂量组、低剂量组,肾上腺髓质(ADM)、一氧化氮(NO)含量高于中等剂量组、低剂量组。中等剂量组中上述指标水平变化趋势大于低剂量组。差异均有统计学意义(P<0.05)。结论:伐地那非是临床治疗新生儿持续肺动脉高压的可靠药物,且药效呈一定剂量依赖性。
Abstract：Objective:To explore the clinical efficacy of different doses of vardenafil for the treatment of neonatal persistent pulmonary hypertension.Methods:60 neonates with persistent pulmonary hypertension were diagnosed and treated in this hospital between August 2013 and April 2017,all of them received vardenafil therapy and they were divided into low dose group(2.5 mg),medium dose group(5 mg)and high dose group(10 mg)according to the doses,20 cases in each group.The differences in pulmonary arterial systolic pressure(PASP)levels as well as the contents of myocardial injury markers and endothelial injury indexes were compared among the three groups of children after 1 month of treatment.Results:After 1 month of treatment,the PASP level in high dose group was lower than that in medium dose group and low dose group;myocardial injury markers hs-cTnT,BNP and LDH contents in peripheral blood were lower than those of medium dose group and low dose group;endothelial injury indexes ET-1 and HIF-1αcontents in peripheral blood were lower than those of medium dose group and low dose group whereas ADM and NO contents were higher than those of medium dose group and low dose group.The change trend of the above indicators in medium dose group was greater than that in low dose group.Conclusion:Vardenafil is a reliable drug for clinical treatment of neonatal persistent pulmonary hypertension,and the efficacy is dose-dependent.
1 Bansal SC,Nimbalkar AS,Kungwani AR,et al.Clinical profile and outcome of newborns with acute kidney injury in a level 3neonatal unit in Western India[J].J Clin Diagn Res,2017,11(3):SC01-SC04.
2 Bakowiec-Iskra E,Mirowska-Guzel DM,Wielgo'S M.Effect of antidepressants use in pregnancy on foetus development and adverse effects in newborns[J].Ginekol Pol,2017,88(1):36-42.
3 Movahedian AH,Mosayebi Z,Sagheb S.Evaluation of pulse oximetry in the early detection of cyanotic congenital heart disease in newborns[J].J Tehran Heart Cent,2016,11(2):73-78.
4 Gagnon MH,Wintermark P.Effect of persistent pulmonary hypertension on brain oxygenation in asphyxiated term newborns treated with hypothermia[J].J Matern Fetal Neonatal Med,2016,29(13):2049-2055.
5 Campbell LJ,Jensen AM.Phosphodiesterase inhibitors sildenafil and vardenafil reduce zebrafish rod photoreceptor outer segment shedding[J].Invest Ophthalmol Vis Sci,2017,58(13):5604-5615.
6 Ried M,Neu R,Lehle K,et al.Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil:additive effects of bosentan[J].Interact Cardiovasc Thorac Surg,2017,25(2):254-259.
7 Noel S,Panin N,Beka M,et al.Vardenafil reduces macrophage pro-inflammatory overresponses in cystic fibrosis through PDE5-and CFTR-dependent mechanisms[J].Clin Sci(Lond),2017,131(11):1107-1121.
8 Mtys C,Németh BT,Olh A,et al.Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5Ainhibitor vardenafil in rats with type 2diabetes[J].Eur J Heart Fail,2017,19(3):326-336.
9 Seo YH,Choi HJ.Clinical utility of echocardiography for early and late pulmonary hypertension in preterm infants:relation with bronchopulmonary dysplasia[J].J Cardiovasc Ultrasound,2017,25(4):124-130.
10 Sato T,Tsujino I,Ohira H,et al.Accuracy of echocardiographic indices for serial monitoring of right ventricular systolic function in patients with precapillary pulmonary hypertension[J].PLoS One,2017,12(11):e0187806.
11 Gy9ngy9si M,Pavo N,Lukovic D,et al.Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension[J].J Transl Med,2017,15(1):202.
12 Friesen RM,Schfer M,Burkett DA,et al.Right ventricular tissue doppler myocardial performance index in children with pulmonary hypertension:relation to invasive hemodynamics[J].Pediatr Cardiol,2018,39(1):98-104.
13 Kallianos K,Brooks GC,Mukai K,et al.Cardiac magnetic resonance evaluation of left ventricular myocardial strain in pulmonary hypertension[J].Acad Radiol,2018,25(1):129-135.
14 Zeng C,Liang B,Jiang R,et al.Protein kinase C isozyme expression in right ventricular hypertrophy induced by pulmonary hypertension in chronically hypoxic rats[J].Mol Med Rep,2017,16(4):3833-3840.
15 Harel F,Langleben D,Provencher S,et al.Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension:aphase II safety and proof of principle trial[J].Eur J Nucl Med Mol Imaging,2017,44(7):1136-1144.
16 Zhang H,Wang D,Li M,et al.Metabolic and proliferative state of vascular adventitial fibroblasts in pulmonary hypertension is regulated through a microRNA-124/PTBP1(polypyrimidine tract binding protein 1)/pyruvate kinase muscle axis[J].Circulation,2017,136(25):2468-2485.
17 Wu K,Zhang Q,Wu X,et al.Chloroquine is a potent pulmonary vasodilator that attenuates hypoxia-induced pulmonary hypertension[J].Br J Pharmacol,2017,174(22):4155-4172.
18 Pan M,Han Y,Si R,et al.Hypoxia-induced pulmonary hypertension in type 2diabetic mice[J].Pulm Circ,2017,7(1):175-185.
19 Duluc L,Ahmetaj-Shala B,Mitchell J,et al.Tipifarnib prevents development of hypoxia-induced pulmonary hypertension[J].Cardiovasc Res,2017,113(3):276-287.
20 Harel F,Langleben D,Provencher S,et al.Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension:aphase II safety and proof of principle trial[J].Eur J Nucl Med Mol Imaging,2017,44(7):1136-1144.
21 Dumas de la Roque E,Smeralda G,Quignard JF,et al.Altered vasoreactivity in neonatal rats with pulmonary hypertension associated with bronchopulmonary dysplasia:Implication of both eNOS phosphorylation and calcium signaling[J].PLoS One,2017,12(2):e0173044.
22 Zhang L,Zhang TX,Liu N,et al.Rosuvastatin alleviates the development of monocrotaline-induced pulmonary hypertension in rats[J].J Biol Regul Homeost Agents,2016,30(3):755-759.
23 Nagaraj C,Tang B,Nagy BM,et al.Docosahexaenoic acid causes rapid pulmonary arterial relaxation via KCa channel-mediated hyperpolarisation in pulmonary hypertension[J].Eur Respir J,2016,48(4):1127-1136.
基本信息:
DOI：10.13210/j.cnki.jhmu.20180207.004
中图分类号:R722.1
引用信息:
[1]易庆军,余静,管利容,等.不同剂量伐地那非治疗新生儿持续肺动脉高压的临床研究[J].海南医学院学报,2018,24(04):552-555.DOI:10.13210/j.cnki.jhmu.20180207.004.
基金信息:
绵阳市中心医院院级课题(2012YJ05)~~
2018-02-07
2018-02-07
2018-02-07